Headlines about Cellular Biomedicine Group (NASDAQ:CBMG) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.8701684670525 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have effected Accern’s rankings:

Shares of Cellular Biomedicine Group (CBMG) remained flat at $8.70 during mid-day trading on Friday. The stock had a trading volume of 12,314 shares. Cellular Biomedicine Group has a 12-month low of $5.05 and a 12-month high of $15.45. The firm’s market capitalization is $122.74 million. The company’s 50 day moving average price is $8.89 and its 200-day moving average price is $9.63.

Cellular Biomedicine Group announced that its board has initiated a share repurchase plan on Thursday, June 1st that permits the company to buyback $10.00 million in shares. This buyback authorization permits the biotechnology company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Separately, Maxim Group set a $18.00 target price on Cellular Biomedicine Group and gave the stock a “buy” rating in a research note on Wednesday, August 9th.

ILLEGAL ACTIVITY NOTICE: “Cellular Biomedicine Group (CBMG) Getting Somewhat Positive Media Coverage, Analysis Finds” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/26/cellular-biomedicine-group-cbmg-getting-somewhat-positive-media-coverage-analysis-finds.html.

In other news, CEO Tony Liu acquired 10,000 shares of Cellular Biomedicine Group stock in a transaction that occurred on Tuesday, June 6th. The stock was purchased at an average price of $6.83 per share, with a total value of $68,300.00. Following the completion of the transaction, the chief executive officer now owns 119,825 shares in the company, valued at $818,404.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 8.20% of the stock is currently owned by company insiders.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

Insider Buying and Selling by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Stock Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related stocks with our FREE daily email newsletter.